West Pharmaceutical Raises 2026 Guidance After Strong Q1 Performance
West Pharmaceutical has increased its revenue and EPS guidance for 2026 following strong Q1 results, indicating positive momentum for the year.
Read postDetailed company information
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 23, 2026
Earnings Transcript for 2026 - Q1Released: Apr 23, 2026
Earnings Transcript for 2025 - Q4Released: Feb 12, 2026
Earnings Transcript for 2025 - Q3Released: Oct 23, 2025
Earnings Transcript for 2025 - Q2Released: Jul 24, 2025
Earnings Transcript for 2025 - Q1Released: Apr 24, 2025
Earnings Transcript for 2024 - Q4Released: Feb 13, 2025
Earnings Transcript for 2024 - Q3Released: Oct 24, 2024
Earnings Transcript for 2024 - Q2Released: Jul 25, 2024
Earnings Transcript for 2024 - Q1Released: Apr 25, 2024
Earnings Transcript for 2023 - Q4Released: Feb 15, 2024
Earnings Transcript for 2023 - Q3Released: Oct 23, 2023
Earnings Transcript for 2023 - Q2Released: Jul 28, 2023
Earnings Transcript for 2023 - Q1Released: Apr 27, 2023
Earnings Transcript for 2022 - Q4Released: Feb 16, 2023
Earnings Transcript for 2022 - Q3Released: Oct 27, 2022
Earnings Transcript for 2022 - Q2Released: Jul 28, 2022
Earnings Transcript for 2022 - Q1Released: Apr 28, 2022
Earnings Transcript for 2021 - Q4Released: Feb 17, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 29, 2021
Earnings Transcript for 2021 - Q1Released: Apr 30, 2021
Earnings Transcript for 2020 - Q4Released: Feb 18, 2021
Earnings Transcript for 2020 - Q3Released: Oct 22, 2020
EMBC Embecta Corp.
West Pharmaceutical has increased its revenue and EPS guidance for 2026 following strong Q1 results, indicating positive momentum for the year.
Read postWest Pharmaceutical has raised its full-year 2026 revenue and EPS guidance following a strong Q1 performance, signaling confidence in continued growth and demand momentum.
Read post